These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

443 related items for PubMed ID: 18951668

  • 21. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
    Hollander N.
    Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
    [Abstract] [Full Text] [Related]

  • 22. Anti-idiotypic antibodies induced by genetic immunisation are directed exclusively against combined V(L)/V(H) determinants.
    Benvenuti F, Burrone OR.
    Gene Ther; 2001 Oct; 8(20):1555-61. PubMed ID: 11704816
    [Abstract] [Full Text] [Related]

  • 23. DNA vaccines for cancer.
    Boyd D, Hung CF, Wu TC.
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [Abstract] [Full Text] [Related]

  • 24. Current status of therapeutic vaccines for non-Hodgkin's lymphoma.
    Hurvitz SA, Timmerman JM.
    Curr Opin Oncol; 2005 Sep; 17(5):432-40. PubMed ID: 16093791
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M.
    Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
    [Abstract] [Full Text] [Related]

  • 27. Vaccination strategies in follicular lymphoma.
    Kannan S, Neelapu SS.
    Curr Hematol Malig Rep; 2009 Oct; 4(4):189-95. PubMed ID: 20425407
    [Abstract] [Full Text] [Related]

  • 28. Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update.
    Marron TU, Ronner L, Martin PE, Flowers CR, Brody JD.
    Immunotherapy; 2016 Nov; 8(11):1335-1346. PubMed ID: 27993085
    [Abstract] [Full Text] [Related]

  • 29. Cloning variable region genes of clonal lymphoma immunoglobulin for generating patient-specific idiotype DNA vaccine.
    Cha SC, Qin H, Sakamaki I, Kwak L.
    Methods Mol Biol; 2014 Nov; 1139():289-303. PubMed ID: 24619688
    [Abstract] [Full Text] [Related]

  • 30. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
    Berinstein NL.
    Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
    [Abstract] [Full Text] [Related]

  • 31. Future of idiotypic vaccination for B-cell lymphoma.
    de Cerio AL, Inogés S.
    Expert Rev Vaccines; 2009 Jan; 8(1):43-50. PubMed ID: 19093772
    [Abstract] [Full Text] [Related]

  • 32. Therapeutic cancer vaccines.
    Morris LF, Ribas A.
    Surg Oncol Clin N Am; 2007 Oct; 16(4):819-31, ix. PubMed ID: 18022546
    [Abstract] [Full Text] [Related]

  • 33. DCs in lymphoma--biology and therapeutic aspects.
    Schultze JL, Fiore F, von Bergwelt-Baildon M.
    Cytotherapy; 2004 Oct; 6(2):138-47. PubMed ID: 15203990
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Idiotype vaccination strategies in myeloma: how to overcome a dysfunctional immune system.
    Rhee Fv.
    Clin Cancer Res; 2007 Mar 01; 13(5):1353-5. PubMed ID: 17332275
    [No Abstract] [Full Text] [Related]

  • 36. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M.
    Curr Opin Mol Ther; 2008 Oct 01; 10(5):526-34. PubMed ID: 18830928
    [Abstract] [Full Text] [Related]

  • 37. Vaccines in lymphoma.
    Levy R.
    Clin Adv Hematol Oncol; 2004 Jul 01; 2(7):424, 427. PubMed ID: 16163215
    [No Abstract] [Full Text] [Related]

  • 38. Feasibility of idiotype vaccination in relapsed B-cell malignancies.
    Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M.
    Haematologica; 2003 Dec 01; 88(12):1438-40. PubMed ID: 14688006
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Current approaches in ovarian cancer vaccines.
    Reinartz S, Wagner U.
    Minerva Ginecol; 2004 Dec 01; 56(6):515-27. PubMed ID: 15729204
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.